Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
Study Details
Study Description
Brief Summary
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD). Healthy volunteers and patients with atopic dermatitis will be studied.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 Pimecrolimus |
Drug: Pimecrolimus
Pimecrolimus cream 1 % bid
Other Names:
|
Placebo Comparator: 2 Placebo control twice daily application |
Drug: Placebo
Placebo application bid
|
Outcome Measures
Primary Outcome Measures
- Determining whether pimecrolimus cream has an effect on the cellular and molecular profile of atopic dermatitis skin, which is cleared of lesions and is otherwise clinically normal. []
Secondary Outcome Measures
- Identifying cellular and molecular changes in skin in an acute phase of atopic dermatitis []
Eligibility Criteria
Criteria
Inclusion Criteria:
Inclusion criteria for patients with atopic dermatitis:
-
Outpatient at screening
-
Adult male >20 years old
-
Diagnosis of AD fulfilling the Hannifin and Rajka criteria
-
Mild to moderate AD (Investigator Global Assessment [IGA] 2-3; localized eczema area and severity index [EASI] 1-8)
-
AD affecting both arms and/or legs >10cm2 per target area
-
Willing to undergo 4 mm serial punch biopsies
-
Patient history of AD for at least 3 years
Inclusion criteria for healthy volunteers:
-
Volunteers must be males >20 years of age
-
Volunteers must be in good health, as determined by past medical history, physical examination, and vital signs
Exclusion Criteria:
Exclusion criteria for patients with atopic dermatitis:
-
Concurrent diseases/conditions and history of other diseases/conditions
-
Are immunocompromised or have a history of malignant disease
-
Have a history of rheumatic fever, heart valve replacement, prosthetic joints or other prosthetic constituents
-
Have concurrent skin disease (e.g. acne) of such severity in the study area that it could interfere with the study evaluation
-
Have previously reported poor or no clinical response to topical tacrolimus ointment (ProtopicĀ®) or pimecrolimus cream (ElidelĀ®)
-
Have active skin infections
-
Present with clinical conditions other than atopic dermatitis that can interfere with the study treatment
-
Present with severe medical condition(s) that, in the opinion of the investigator, prohibits participation in the study
-
Are maintained on emollients that contain supplementary ingredients such as urea, alpha or beta-hydroxy acids, fruit acids, vitamins A, D or E
-
Have received phototherapy (e.g. UVA, UVB) or systemic therapy (e.g. immunosuppressants, cytostatics) known or suspected to have an effect on AD within 4 weeks of Visit 1 (screening)
-
Have received systemic corticosteroids ([CS] e.g. oral, intravenous, intraarticular, rectal) within 4 weeks of Visit 1 (screening). Patients on a stable maintenance dose of inhaled or intranasal CS may participate
-
Were treated with topical therapy, including topical calcineurin inhibitors (e.g. corticosteroids, tar) known or suspected to have an effect on AD during the current acute episode
-
Were treated with antihistamines within 7 days of Visit 1
-
Known serious adverse reactions or hypersensitivity to anesthetics such as lidocaine or mepivacaine
-
Excluded investigational drugs/hypersensitivity
-
Have received investigational drugs within 8 weeks of the first application of study drug or planned use of other investigational drugs during participation in this study
-
Have known hypersensitivity to any ingredient of the pimecrolimus cream 1% or this class of study drug
Exclusion criteria for healthy volunteers:
-
Erythrodermic patients, patients with Netherton's syndrome
-
Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)
-
Clinically significant findings during the physical examination
-
Have a history of rheumatic fever, heart valve replacement, prosthetic joints or other prosthetic constituents e.g. lens implants or hip joints
-
Volunteers with known serious adverse reactions or hypersensitivity to anesthetics such as lidocaine or mepivacaine
-
Participation in any clinical trial within one month prior to current trial
-
History of immunocompromise
-
History of positive hepatitis B surface antigen (HBsAg) or hepatitis C test result
-
Use of corticosteroids within 4 weeks prior to baseline
-
Were treated with antihistamines within 7 days of Visit 1
-
Phototherapy within 4 weeks prior to baseline
-
Topical therapy within 5 weeks prior to the study
-
Treatment with nephrotoxic drugs within 2 weeks prior to baseline (aminoglycosides, amphotericin B, colchicine)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mount Sinai School of Medicine | New York | New York | United States | |
2 | New York University Hospital | New York | New York | United States | |
3 | Virginia Clinical Research, Inc | Norfolk | Virginia | United States |
Sponsors and Collaborators
- Novartis
Investigators
- Study Chair: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CASM981C2436